Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Withdrawn 2Unknown 1Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 6Other hematologic neoplasm 3Gynecologic 2Gastrointestinal 2Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1

Interventions

Cisplatin 108Radiotherapy 44Docetaxel 44Radiotherapy, Intensity-Modulated 35Gemcitabine 31Fluorouracil 30camrelizumab 24toripalimab 21Drug Therapy 21Cetuximab 20apatinib 19Paclitaxel 16Carboplatin 16pembrolizumab 14Chemoradiotherapy 14Capecitabine 13sintilimab 12nimotuzumab 12Blood Specimen Collection 11Surveys and Questionnaires 10Surgical Procedures, Operative 10Endostatins 10Cyclophosphamide 9nedaplatin 8endostar protein 8durvalumab 8Nivolumab 8Neoadjuvant Therapy 8Induction Chemotherapy 8fludarabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Microarray Analysis × Head & Neck × Clear all
NCT00357617 2010-12-24

Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1/2 Unknown
24 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡